TPA Immobilization on Iron Oxide Nanocubes and Localized Magnetic Hyperthermia Accelerate Blood Clot Lysis
Source abstract
Abstract
The low specificity and high risk of intracranial hemorrhage associated with currently approved thrombolytic therapies limit their efficacy in recanalizing occluded vessels. Here, a nanoscale thrombolytic agent is demonstrated by immobilizing tissue plasminogen activator molecules (tPA) over 20 nm clustered iron oxide nanocubes (NCs). The resulting nanoconstructs (tPA–NCs) are capable of dissolving clots via both direct interaction of tPA with the fibrin network (chemical lysis) and localized hyperthermia upon stimulation of superparamagnetic NCs with alternating magnetic fields (AMFs) (mechanical lysis). In vitro, as compared to free tPA, the proposed nanoconstructs demonstrate a ≈100‐fold increase in dissolution rate, possibly because of a more intimate interaction of tPA with the fibrin network. The clot dissolution rate is further enhanced (≈10‐fold) by mild, localized heating resulting from the exposure of tPA–NCs to AMF. Intravital microscopy experiments demonstrate blood vessel reperfusion within a few minutes post tail vein injection of tPA–NCs. The proposed nanoconstructs also exhibit high transverse relaxivity (>400 × 10–3 m−1 s−1) for magnetic resonance imaging. The multifunctional properties and the 3 orders of magnitude enhancement in clot dissolution make tPA–NCs a promising nano‐theranosis agent in thrombotic disease.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Acute Ischemic Stroke Management · Blood properties and coagulation · Intracerebral and Subarachnoid Hemorrhage Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Translational Imaging Houston Methodist Research Institute Houston TX 77030 USA
Department of Nanomedicine Houston Methodist Research Institute Houston TX 77030 USA
Houston Methodist DeBakey Heart and Vascular Center Houston Methodist Hospital Houston TX 77030 USA
Department of Drug Discovery and Development Fondazione Istituto Italiano di Tecnologia Genoa 16163 Italy
References (54)
Show source-provided references
1. 10.1056/NEJMra080108210.1056/NEJMra0801082 ↗
2. 10.1160/TH10-10-068310.1160/TH10-10-0683 ↗
3. 10.1182/blood-2013-04-46016210.1182/blood-2013-04-460162 ↗
4. 10.1038/clpt.2009.9810.1038/clpt.2009.98 ↗
5. 10.1038/nature0679710.1038/nature06797 ↗
6. 10.1016/j.thromres.2008.08.00310.1016/j.thromres.2008.08.003 ↗
7. 10.1161/STROKEAHA.107.18148610.1161/STROKEAHA.107.181486 ↗
8. 10.1056/NEJMoa080465610.1056/NEJMoa0804656 ↗
9. 10.1038/nrneurol.2009.12710.1038/nrneurol.2009.127 ↗
10. 10.1056/NEJM19951214333240110.1056/NEJM199512143332401 ↗
11. 10.1111/j.1552-6569.2004.tb00225.x10.1111/j.1552-6569.2004.tb00225.x ↗
12. 10.1159/00020312710.1159/000203127 ↗
13. 10.7863/ultra.32.7.111710.7863/ultra.32.7.1117 ↗
14. 10.1111/jon.1202610.1111/jon.12026 ↗
15. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
16. 10.1038/nrc156610.1038/nrc1566 ↗
17. 10.1007/s00395-008-0710-710.1007/s00395-008-0710-7 ↗
18. 10.1021/ar200106e10.1021/ar200106e ↗
19. 10.1002/jmri.2086610.1002/jmri.20866 ↗
20. 10.1016/j.jconrel.2009.10.01410.1016/j.jconrel.2009.10.014 ↗
21. 10.1016/j.biomaterials.2013.03.07810.1016/j.biomaterials.2013.03.078 ↗
22. 10.1111/j.1538-7836.2011.04339.x10.1111/j.1538-7836.2011.04339.x ↗
23. 10.1021/mp400210q10.1021/mp400210q ↗
24. 10.1007/s11239-013-0951-710.1007/s11239-013-0951-7 ↗
25. 10.1016/j.jacc.2012.08.100810.1016/j.jacc.2012.08.1008 ↗
26. 10.2217/nnm.11.17910.2217/nnm.11.179 ↗
27. 10.1126/science.121781510.1126/science.1217815 ↗
28. 10.2217/nnm.11.12810.2217/nnm.11.128 ↗
29. 10.1021/ja808690610.1021/ja8086906 ↗
30. 10.1021/am504270c10.1021/am504270c ↗
31. 10.1016/j.nurt.2010.07.00510.1016/j.nurt.2010.07.005 ↗
32. 10.1016/0049-3848(95)93883-210.1016/0049-3848(95)93883-2 ↗
33. 10.1046/j.1460-9568.1999.00856.x10.1046/j.1460-9568.1999.00856.x ↗
34. 10.1371/journal.pone.005733210.1371/journal.pone.0057332 ↗
35. 10.1007/s00418-010-0692-z10.1007/s00418-010-0692-z ↗
36. 10.1084/jem.2002094510.1084/jem.20020945 ↗
37. 10.1021/nn305719y10.1021/nn305719y ↗
38. 10.2967/jnumed.113.12226710.2967/jnumed.113.122267 ↗
39. 10.1016/j.bbagen.2010.04.00710.1016/j.bbagen.2010.04.007 ↗
40. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
41. Ventola C. L. · P & T · 2012 · 37 · 582
42. 10.1186/1477-3155-11-S1-S610.1186/1477-3155-11-S1-S6 ↗
43. 10.1166/jnn.2014.900810.1166/jnn.2014.9008 ↗
44. Dianzani C. · Biomed. Res. Int. · 2014 · 895986
45. 10.1016/j.ejps.2008.06.01210.1016/j.ejps.2008.06.012 ↗
46. 10.2147/IJN.S3619710.2147/IJN.S36197 ↗
47. 10.1038/nnano.2007.21710.1038/nnano.2007.217 ↗
48. 10.1161/hc3601.09430310.1161/hc3601.094303 ↗
49. 10.1016/j.ultrasmedbio.2006.10.01010.1016/j.ultrasmedbio.2006.10.010 ↗
50. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
51. 10.1021/nl301030810.1021/nl3010308 ↗
52. 10.1016/j.mad.2006.01.02310.1016/j.mad.2006.01.023 ↗
53. 10.1016/0049-3848(89)90009-110.1016/0049-3848(89)90009-1 ↗
54. Francis C. W. · Thromb. Haemostasis · 1995 · 73 · 38610.1055/s-0038-1653785 ↗